NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, reported a net loss of $10.1 million for the year ended December 31, 2023, with a similar loss of $10.5 million for the previous year. As of December 31, 2023, the company had an accumulated deficit of $26.1 million and cash and cash equivalents of $2.6 million. The company's financial statements have been prepared on a going concern basis, indicating the possibility of a significant doubt about its ability to continue as a going concern without additional financing. NeuroSense's operating expenses primarily consist of research and development for their lead product candidate, PrimeC, aimed at treating neurodegenerative diseases such as ALS. The company has not generated any revenue to date and expects to incur significant expenses as it continues clinical trials and seeks regulatory approvals. NeuroSense has financed operations through public and private equity offerings, warrant and option exercises, and crowd funding. The company's future funding requirements will depend on various factors, including the progress of clinical trials, regulatory approvals, and potential commercialization of its product candidates.

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, reported a net loss of $10.1 million for the year ended December 31, 2023, with a similar loss of $10.5 million for the previous year. As of December 31, 2023, the company had an accumulated deficit of $26.1 million and cash and cash equivalents of $2.6 million. The company's financial statements have been prepared on a going concern basis, indicating the possibility of a significant doubt about its ability to continue as a going concern without additional financing. NeuroSense's operating expenses primarily consist of research and development for their lead product candidate, PrimeC, aimed at treating neurodegenerative diseases such as ALS. The company has not generated any revenue to date and expects to incur significant expenses as it continues clinical trials and seeks regulatory approvals. NeuroSense has financed operations through public and private equity offerings, warrant and option exercises, and crowd funding. The company's future funding requirements will depend on various factors, including the progress of clinical trials, regulatory approvals, and potential commercialization of its product candidates.